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doi:10.101Umbilical Cord Blood Transplantation for Children
with Thalassemia and Sickle Cell Disease
Annalisa Ruggeri,1 Mary Eapen,2 Andromachi Scaravadou,3 Mitchell S. Cairo,4
Monica Bhatia,4 Joanne Kurtzberg,5 John R. Wingard,6 Anders Fasth,7 Luca Lo Nigro,8
Mouhab Ayas,9 Duncan Purtill,1 Karim Boudjedir,1 Wagnara Chaves,1 Mark C. Walters,10
JohnWagner,11 ElianeGluckman,1 VandersonRocha,1,12 for theEurocordRegistry, theCenter for
International Blood and Marrow Transplant Research, and the New York Blood CenterWe examined the efficacy of unrelated cord blood (CB) transplantation in children with thalassemia (n5 35)
and sickle cell disease (n 5 16), using data reported to 3 registries. Donor-recipient pairs were matched at
HLA-A and -B (antigen level) and DRB1 (allele level) in 7 or HLA mismatched at 1 (n 5 18), 2 (n 5 25), or
3 loci (n5 1). Transplant conditioning was myeloablative (n5 39) or reduced intensity (n5 12). Neutrophil
recovery with donor chimerism was documented in 24 patients; 11 patients developed grade II-IV acute graft-
versus-host disease (aGVHD) and 10 patients, chronic GVHD (cGVHD).Overall survival (OS) and disease-free
survival (DFS) were 62% and 21% for thalassemia and 94% and 50% for sickle cell disease (SCD), respectively. In
multivariate analysis, engraftment rate (hazard ratio [HR] 2.2, P5 .05) and DFS (HR 0.4, P5 .01) were higher
with cell dose .5  107/kg. The 2-year probability of DFS was 45% in patients who received grafts with cell
dose.5 107/kg and 13% with lower cell dose. Primary graft failure was the predominant cause of treatment
failure occurring in 20 patients with thalassemia and 7 patients with SCD. Primary graft failure was fatal in 5
patients with thalassemia. These results suggest that only CB units containing an expected infused cell dose
.5  107/kg should be considered for transplantation for hemoglobinopathy.
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Transplantation of hematopoietic stem cells (HSC)
from a HLA matched sibling including umbilical cord
blood (CB) has been used successfully for thalassemia
and sickle cell disease (SCD) [1,2]. Disease-free survival
(DFS) rates approach 80% to 90%with transplantation
of bone marrow (BM) for sickle cell disease [3,4] and
80% to 95% for beta-thalassemia [5,6]. Despite the
availability of over 14 million potential unrelated adult
donors registered worldwide, only approximately 17%
of African Americans and 20% of Asians who may
benefit from unrelated donor transplantation are able
to identify a HLA matched unrelated adult donor [7].
As advances in supportive care after transplantation
in recent years have led to improvements in survival
for patients with hemoglobinopathy [8,9], alternative
donor sources such as HLA mismatched family
members or unrelated CB units are being explored
for patients with hemoglobinopathy. Recent reports
suggest DFS rates of approximately 70% for patients
with thalassemia who received transplants of allele-
level HLA matched unrelated donor BM [10], and1375
1376 Biol Blood Marrow Transplant 17:1375-1382, 2011A. Ruggeri et al.similar results are also reported after haploidentical
donor transplants [11].
Unrelated cord blood transplantation (CBT) has
been explored as an alternative option for these pa-
tients without a suitably HLAmatched unrelated adult
donor. Tolerability of HLA mismatch with relatively
low rates of acute and chronic graft-versus-host disease
(aGVHD, cGVHD), make CBT a potentially attrac-
tive option for those with a hemoglobinopathy. How-
ever, CBT may be limited by less than adequate cell
dose and higher rates of primary graft failure [12-14].
In a recent report from Taiwan, 27 of 32 patients
with thalassemia were disease free at 2 years after
CBT with myeloablatve conditioning regimens [15].
In contrast, 4 of 7 patients with SCD after CBT had
primary graft failure; importantly, 3 of these 4 patients
received reduced-intensity conditioning (RIC) regi-
mens [16]. In the absence of conclusive recommenda-
tions on CBT for thalassemia and SCD, we examined
outcomes after CBT using data reported to Eurocord,
the National Cord Blood Program (NCBP), New
York Blood Center, and the Center for International
Blood and Marrow Transplant Registry (CIBMTR)
to determine the state of the field at the present time.PATIENTS, MATERIALS, AND METHODS
Patients
Patientswithhemoglobinopathywhoreceived trans-
plants of a single unmanipulated CB unit and who were
without a history of prior HSC transplantation were eli-
gible; 35 patients had thalassemia, and 16 patients had
SCD. Patients reported to 2 or more registries (n 5 6)
were identified, and each patient included in the current
analysis represents a ‘‘unique case.’’ CBT were per-
formed at 32 transplant centers between 1996 and
2009.The studywas approvedby the institutional review
board,Medical College ofWisconsin and theEurocord-
Netcord scientific committee. Myeloablative condition-
ing regimenwas defined as oral (p.o.) busulphan$8mg/
kg or intravenous (i.v.) busulphan $6.4 mg/kg, or mel-
phalan $150 mg/m2, or total-body irradiation (TBI)
($6 Gy) were used.
Endpoints
Neutrophil recovery was defined as achieving
absolute neutrophil count (ANC) $0.5  109/L for 3
consecutive days with sustained donor engraftment as-
sessed by chimerism assay ($95% donor). The timing
and method of assay were at the discretion of the trans-
plant center. Primary graft failure was defined as having
never achieved ANC $0.5  109/L or ANC $0.5 
109/L without donor engraftment (autologous recov-
ery). Secondary graft failure was defined as having
achieved ANC $0.5  109/L with subsequent decline
to\0.5  109/L or loss of donor engraftment. Plateletrecoverywas defined as achieving platelets$20 109/L
unsupported by platelet transfusions for 7 days. The
diagnosis and grading of aGVHD and cGVHD was
assigned by the transplant center using standard criteria
[17,18]. DFS was defined as being alive with donor
chimerism. Graft failure, second transplant, and death
from any cause were considered events.
Statistical Analysis
Median value and ranges are reported for continu-
ous variables and percentages for categoric variables
(Table 1). The probabilities of overall survival (OS)
and DFS were calculated using the Kaplan-Meier esti-
mator and the log-rank test for univariate comparisons
[19]. The probabilities of neutrophil engraftment,
grade acute 2-4 and cGVHD were calculated with
the cumulative incidence estimator. Multivariate anal-
yses were performed using Cox proportional hazards
regression model for DFS and OS, and Fine and
Gray’s proportional hazards regression model [20,21].
The variables evaluated included recipient age, do-
nor sex, disease duration before UCBT, ABO compat-
ibility, HLA matching high-resolution DNA typing,
number of total nucleated cells (TNCs) at the time
of freezing and infusion, conditioning regimen, and
year of UCBT. Each potential risk factor was tested in-
dependently. All factors that reached a P value5 .10 in
the univariate analysis were included in the multivari-
ate model. All models were built using a forward step-
wise method. Only factors that reached P value #.05
were retained in the final model. Patients were cen-
sored at death if they underwent a second transplant
or for surviving patients, at last follow-up. P values
are 2 sided. Statistical analyses were performed with
SPSS (Inc., Chicago, IL) and Splus (MathSoft, Inc,
Seattle, WA).RESULTS
Patient, Disease, and Transplant Characteristics
Patient, disease, and transplant characteristics are
shown in Table 1. The indications for transplantation
were a history of stroke (n 5 12) and acute chest syn-
drome or vaso-occlusive crisis (n 5 4) in patients with
SCD. As transplantations occurred worldwide and con-
sistent with published reports, the Pesaro risk score was
not assigned pretransplant for all patients with thalasse-
mia; only 15 of 35 patients had sufficient data for assign-
ment of the Pesaro classification: class 1 (n5 9), class 2
(n 5 2), and class 3 (n 5 4). Patients with thalassemia
were younger (median, 4 years) compared to those
with SCD (median, 6 years). Only 7 donor-recipient
pairs were matched at HLA-A and -B (antigen level)
and DRB1 (allele level) with the remaining mismatched
at 1 (n 5 18), 2 (n 5 25), or 3 HLA loci (n 5 1).
Myeloablative conditioning regimens were used in 30
Table 1. Patient, Disease, and Transplant Characteristics
Thalassemia
Sickle Cell
Disease
Number evaluation 35 16
Sex male, % 58% 75%
Interval from diagnosis to transplant, months 29 (3-169) 76 (7-191)
Conditioning regimen
Myeloablative regimens, n 30 9
Busulfan + cyclophosphamide (Cy) + ATG 27 6
Busulfan + fludarabine + Cy 2 —
Busulfan + fludarabine — —
Busulfan + Cy +Thiotepa + ATG 1 —
Busulfan + fludarabine + alemtuzumab — 1
Busulfan + melphalan — 1
Busulfan + melphalan + ATG — 1
Reduced-intensity regimens, n 5 7
Busulfan + fludarabine + TLI +
ATG/alemtuzumab
1 2
Melphalan + fludarabine + ATG/alemtuzumab 1 2
Cy + fludarabine ± TLI + ATG/alemtuzumab 2 3
Fludarabine ± TB 200 Gy 1 —
Use of ATG/Campath before day 0, % 86% 94%
GVHD prophylaxis
Cyclosporine based,n, % 27 (80%) 9 (54%)
Tacrolimus based, n, % 8 (20%) 7 (46%)
Donor-recipient HLA match, n
6/6 matched 5 2
5/6 matched 14 4
4/6 matched 15 10
3/6 matched 1 —
Total nucleated cell dose, at
collection/kg (107)
6 (2-32) 6 (2-12)
Total nucleated cell dose, infused/kg (107) 5 (2.4-23) 4.9 (1.1-9)
Median follow-up of surviving patients 21 (3-138) 37 (3-80)
GVHD indicates graft-versus-host disease; ATG, antithymocyte globulin;
YLI, total lymphoid irradiation.
Biol Blood Marrow Transplant 17:1375-1382, 2011 1377Unrelated Cord Blood for Hemoglobinopathiesof 35 patients with thalassemia and 9 of 16 with SCD.
Busulfan and cyclophosphamide with or without anti-
tyhmocyte globulin (ATG) was the most common
myeloablative-conditioning regimen. Twelve patients
received RIC and all except 1 received in vivo T cell de-
pletion (ATG or alemtuzumab). All patients received
calcinuerin inhibitor containing GVHD prophylaxis,
and cyclosporine was the most common agent (65%).
The median follow-up of surviving patients with thalas-
semia and SCD was 21 and 37 months, respectively.Engraftment and Graft Failure
Twenty-four of 51 patients (n5 15 thalassemia; n5
9 SCD) achieved neutrophil recoverywith complete do-
nor chimerism. The median time to neutrophil recov-
ery was 22 days (range: 10-62 days). Two patients had
mixed chimerism prior to day 100 but subsequently
achieved complete donor chimerism. None of the pa-
tients experienced secondary graft failure. In multivari-
ate analysis, engraftment (neutrophil recovery with full
donor chimerism) was higher in recipients who received
CB units with infused total nucleated cell dose of.5
107nucleated cells/kg (hazard ratio [HR] 2.2, 95%
confidence interval [CI], 0.96-3.6, P 5 .05). The
day 60 cumulative incidence of engraftment was 63%6 9% with CB units containing .5  107 nucleated
cells/kg and 32% 6 8% with lower cell dose CB units.
The median time to platelet recovery was 40 days
(range: 15-127days).Aswithneutrophil recovery, plate-
let recovery was higher with transplantation ofCB units
containing total nucleated cells .5  107/kg (HR 3.4,
95% CI, 1.2-6.2, P5 .02). The day 180 cumulative in-
cidence of platelet recovery was 68% 6 9% with CB
units containing.5 107 nucleated cells/kg compared
to 25%6 9% with CB units containing a lower dose.
The characteristics and outcome of the 24 patients
who engrafted are shown in Table 2A. Nineteen pa-
tients received myeloablative conditioning regimens
and 5, RIC regimens. The characteristics of the 27 pa-
tients with primary graft failure and their outcome are
shown in Table 2B. The cumulative incidence of graft
failure was 52% at day 60 and at 1 year. Twenty patients
received myeloablative conditioning regimens and 7,
RIC regimens. Of these patients with graft failure, 18
had autologous reconstitution, 3 patients received their
autologous back-up for prolonged neutropenia and ab-
sence of chimerism, 4 patients died without neutrophil
recovery, and 2 patients underwent a second allogeneic
transplant. Both recipients of second allogeneic HSC
transplant are alive with complete donor chimerism
with the donor of the second transplant.Acute GVHD and cGVHD
Eleven patients developed grade 2-4 aGVHD
(grade 2 in 8; grade 3 in 2; grade 4 in 1). The cumula-
tive incidence of grade 2-4 aGVHD at day 100 was
23%6 2%.Ten patients developed cGVHD.Chronic
GVHD was extensive in 2 patients and limited in the
remaining 8 patients. The cumulative incidence of
cGVHD at 2 years was 16% 6 4%.DFS and OS
Only 16 of 51 patients are alive and disease free
(SCD, n 5 8; thalassemia, n 5 8). DFS was lower in
patients with thalassemia (21% 6 7% compared to
50%6 9% for SCD, P5 .05) (Figure 1). In multivar-
iate analysis, DFS was higher with CB units containing
total nucleated cell dose .5  107/kg (HR 0.4, 95%
CI, 0.2-0.8, P5 .01). The effect of TNC onDFS is in-
dependent of disease. The 2-year probability of DFS
was 45% 6 9% in recipients of CB units containing
a cell dose .5  107/kg compared to 13% 6 7% for
lower cell dose. Although only 16 patients are alive
and cured of their disease, 38 of 51 patients are alive
largely because of autologous reconstitution after
transplantation. All SCD patients with autologous
recovery are alive, whereas there were 5 deaths in the
thalassemia group. The probabilities of OS for pa-
tients with thalassemia and SCD are 62% 6 9% and
94% 6 6%, respectively (Figure 2).
Table 2A. Characteristics of Patients Who Engrafted with Donor Chimerism
Patient Age, Years Diagnosis
Median Disease
Duration, Months Conditioning Regimen
GVHD
Prophylaxis
Donor-Recipient
HLA Match
TNC Infused,
(107/kg)
Follow-Up,
Months Status Cause of Death
1 8 Sickle cell disease 20 Cy+Bu+ATG FK506 5/6 matched — 23.93 alive
2 9 Sickle cell disease 106 Cy+Bu+ATG CsA+Pred 5/6 matched 6.9 63.50 alive
3 6 Sickle cell disease 76 Bu+Fluda+Alemtuzumab* FK506+MMF 4/6 matched 3.5 37.22 alive
4 8 Sickle cell disease 97 Fluda+Melph+Alemtuzumab* CsA+MTX+Pred 4/6 matched — 11.64 alive
5 5 Sickle cell disease Cy+Bu+Fluda CsA+Pred 5/6 matched 11 2.41 dead GVHD
6 3 Sickle cell disease 39 Cy+Bu+ATG FK506+Pred 4/6 matched 9.3 80.50 alive
7 3 Sickle cell disease 37 Cy+Bu+ATG CsA+Pred 6/6 matched 5.1 20.53 alive
8 12 Sickle cell disease 151 Cy+Bu+ATG Other 4/6 matched 1.7 79.44 alive
9 4 Sickle cell disease 54 Cy+Fluda+Alemtuzumab* FK506+MMF 4/6 matched 9.1 29.62 alive
10 4 Thalassemia 26 Cy+Bu+ATG CsA+Pred 4/6 matched 7.1 10.74 dead Unknown
11 1 Thalassemia 15 Cy+Bu+Fluda CsA+MMF 5/6 matched 15.2 11.57 alive
12 0.3 Thalassemia 4 Cy+Fluda* CsA+Pred 6/6 matched 3.9 3.01 dead Veno-occlusive disease
13 15 Thalassemia — Cy+Bu+ATG CsA 4/6 matched 3.3 5.88 dead MOF
14 2 Thalassemia 20 Cy+Bu+ATG CsA+Pred 5/6 matched 4.9 44.36 alive
15 8 Thalassemia 101 Cy+Bu+ATG CsA+Pred 4/6 matched 4.3 14.21 dead Infection
16 1 Thalassemia — Fluda+Melph+ATG* Other 6/6 matched 7.6 7.40 alive
17 5 Thalassemia 3 Cy+Bu+ATG FK506 5/6 matched 8.7 4.43 alive
18 4 Thalassemia 64 Cy+Bu+ATG Other 5/6 matched 7.4 5.88 dead Hemorrhage
19 2 Thalassemia 26 Cy+Bu+ATG CsA+Pred 4/6 matched 1.4 5.88 dead Interstitial pneumonitis
20 3 Thalassemia 43 Cy+Bu+ATG FK506+MMF 6/6 matched 11 5.72 alive
21 0.2 Thalassemia 7 Cy+Bu+ATG CsA+Pred 4/6 matched 1.9 91.07 alive
22 1 Thalassemia — Cy+Bu+ATG CsA+MTX 5/6 matched 9.6 1.49 alive
23 5 Thalassemia 29 Cy+Bu+ATG CsA+MMF+ Pred 5/6 matched 7.1 5.02 dead Infection
24 2 Thalassemia 19 Cy+Bu+ATG FK506 5/6 matched 5.1 37.26 alive
ATG indicates serum antilymphocyt; Bu, busulfan; CsA, cyclosporine A; Cy cyclophosfamide; Fluda, fludarabine; Melph, melphalan; MMF, mycophenolate mofetil; MTX, methotrexate; MOF, multiorgan failure; Pred,
prednisone.
*Reduced-intensity conditioning.
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Table 2B. Characteristics of Patients with Primary Graft Failure
Patient Age, Years Diagnosis
Median Disease
Duration, Months
Conditioning
Regimen
aGVHD
Prophylaxis
Donor-Recipient
HLA Match
TNC Infused,
(107/kg)
Follow-Up,
Months Status
Cause
of Death
1 6 Sickle cell disease 77 Cy+Bu+ATG FK506 4/6 matched 5.6 72.36 alive
2 5 Sickle cell disease 59 Bu+Fluda+TLI+ATG‡ CsA+MMF 6/6 matched 5.8 29.52 alive
3 9 Sickle cell disease 107 Bu+Melph+ATG CsA 5/6 matched 3 41.22 alive
4 1 Sickle cell disease 7 Cy+Fluda‡ FK506+MMF 4/6 matched 4.7 22.12 alive
5 5 Sickle cell disease 62 Cy+Bu+ATG FK506 4/6 matched 4.2 3.57 alive
6 8 Sickle cell disease 100 Cy+Fluda+TLI+ATG‡ CsA+Pred 4/6 matched 4 45.29 alive
7 17 Sickle cell disease 191 Fluda+Melph+ATG‡ CsA+Pred 4/6 matched 1.4 56.23 alive
8* 0/5 Thalassemia 6 Bu+Fluda FK506+MMF 5/6 matched 9.52 75.57 alive
9 15 Thalassemia 73 Cy+Bu Other 3/6 matched 3.7 24.33 alive
10 10 Thalassemia 96 Cy+Bu CsA+MTX 5/6 matched 3.2 16.66 alive
11 6 Thalassemia 69 Cy+Bu+ATG CsA+MMF+Pred 5/6 matched 3.3 7.07 alive
12 2 Thalassemia 22 Cy+Bu+ATG CsA 5/6 matched 15 21.36 alive
13† 11 Thalassemia 124 Cy+Bu+ATG CsA+Pred 5/6 matched 2.6 45.75 alive
14 6 Thalassemia 57 Cy+Bu+ATG Other 6/6 matched 5.8 17.95 alive
15* 1 Thalassemia 9 Bu+Fluda+TLI+ATG§ CsA+MMF 4/6 matched 5.3 43.54 alive
16 4 Thalassemia 46 Fluda+Melph+ATGh‡ FK506 6/6 matched 3.7 35.37 alive
17 7 Thalassemia 33 Cy+Bu+ATG CsA+Pred 4/6 matched 4.5 0.07 dead ARDS
18 6 Thalassemia 28 Cy+Bu+ATG CsA+MMF 5/6 matched 9.2 0.46 dead ARDS
19 1 Thalassemia 5 Cy+Bu+ATG CsA+Pred 4/6 matched 23.3 0.5 dead ARDS
20 2 Thalassemia 23 Cy+Bu+ATG CsA+MMF 4/6 matched 6.5 12.1 alive
21 2 Thalassemia 30 Cy+Bu+ATG Other 4/6 matched 4.9 6.41 alive
22 14 Thalassemia 169 Fludarabine‡ CsA+MMF 4/6 matched 3.7 2.51 dead Infection
23 8 Thalassemia 97 Cy+Bu+ATG CsA+Pred 4/6 matched 4.8 27.93 alive
24† 2 Thalassemia 25 Cy+Bu+ATG CsA+Pred 5/6 matched 4.6 137.88 alive
25 9 Thalassemia 98 Cy+Bu+ATG Other 4/6 matched 2.4 0.79 dead Infection
26 6 Thalassemia 74 Cy+Bu+ATG CsA 4/6 matched 3.7 25.62 alive
27† 1 Thalassemia 4 Cy+Bu+Thio+ATG CsA 4/6 matched 12 13.65 alive
aGVHD indicates acute graft-versus-host disease; ARDS, acute respiratory distress syndrome; ATG, serum antilymphocyt; Bu, busulfan; CsA, cyclosporine A; Cy, cyclophosfamide; Fluda, fludarabine; Melph,
melphalan; MMF, mycophenolate mofetil; MTX, methotrexate; Thio, Thiotepa; Pred, prednisone; TNC, total nuclease cell; TLI, total lymphoid irradiation.
*Second hematopoietic stem cell transplantation (HSCT).
†Autologous backup.
‡Reduced-intensity conditioning (RIC).
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1380 Biol Blood Marrow Transplant 17:1375-1382, 2011A. Ruggeri et al.Thirteen patients are dead. Twelve of these
patients were transplanted for thalassemia; 7 of these
patients had engrafted and died of transplant-related
complications. The remaining 5 patients had primary
graft failure. Deaths in patients with graft failure may
be attributed to patient selection rather than the graft
type, a hypothesis that is difficult to test when using
data collected by registries. One patient with SCD is
dead as a result of severe aGVHD. There were 7 early
deaths (#100 days after transplantation) because of in-
fection (n 5 2), adult respiratory distress syndrome
(n 5 3), veno-occlusive disease (n 5 1), and GVHD
(n5 1). Causes of death beyond 100 days were because
of opportunistic infection (n5 2), hemorrhage (n5 1),
interstitial pneumonitis (n5 1), and multiorgan failure
(n5 1). Cause of death was not reported for 1 patient.Figure 1. Estimated 2-year DFS according to diagnosis ( sickle cell
disease; — thalassemia).
Figure 2. Estimated 2-year OS according to diagnosis ( sickle cell
disease; — thalassemia.DISCUSSION
Allogeneic HSC transplantation offers the only
chance of cure for patients with thalassemia major and
SCD. However, during the last 3 decades, the medical
management of thalassemia or SCD, based primarily
on hypertransfusion programs and appropriate chela-
tion treatment or on the use of hydroxyurea, has im-
proved survival of those patients [9,22]. Conventional
therapy requires strict compliance of the patients,
and therefore the real benefit of an allogeneic
transplantation should take these developments into
consideration, before indication of such a procedure.
In fact, transplantation of BM from a HLA matched
sibling remains the standard of care when such a donor
is available, with cure rates of 85% for both diseases
[4,5,23]. OS after related HLA-matched sibling donor
CB transplants are similar to OS after BM transplants
in children with malignant and nonmalignant diseases
[24], and the same results were observedwhen analyzing
only patients with thalassemia and SCD transplanted
with CB or BM from HLA identical sibling donors
[25]. Yet another recent approach in the setting of
HLA matched sibling transplantation, in order to de-
crease mortality related to the transplantation proce-
dure, is the use of CD34-selected peripheral blood and
a RIC [26]. Of 10 patients treated, 9 patients achieved
engraftment with mixed chimerism. Longer follow-up
is required to determine whether ‘‘mixed chimerism’’
is stable and capable of curing these patients and elimi-
nating the end-organ effects of the underlying disease.
Interestingly, mixed chimerism was not associated
with an increased riskof graft failure in a seriesof 27chil-
dren with beta-thalassemia who received transplants of
CB from a related donor [27].
However, as few patients have a HLAmatched sib-
ling donor, most rely on alternative donor transplanta-
tion for cure. Transplantation of BM from a HLA
matched unrelated adult donor coupled with myeloa-blative transplant conditioning for thalassemia major
approach 80% of survival rate [10,28]. In a recent
report, using maternal donors, 14 of 22 patients were
reported alive and disease-free with a median follow-
up of 40 months [11].
Another alternative donor possibility is the use of
cord blood cells; however, there are very few reports
on the outcomes after this procedure in patients with
hemoglobinopathies. To our knowledge, the current
Biol Blood Marrow Transplant 17:1375-1382, 2011 1381Unrelated Cord Blood for Hemoglobinopathiesanalysis is the largest to date on the impact of UCBT in
the treatment of thalassemia and SCD. Engraftment,
DFS, and OS for thalassemia are inferior to that re-
ported after unrelated adult donor BM transplanta-
tion, and primary graft failure was the most common
cause of treatment failure. Graft failure accounted
for 25% of deaths in patients with thalassemia. Graft
failure was also the most common cause of treatment
failure for SCD. However, all patients with SCD
who experienced graft failure had autologous reconsti-
tution and are alive. Our findings are consistent with
that of others [3,29]. Death from treatment-related
complications was common in patients with thalasse-
mia; infection and pulmonary complications were the
most common causes of treatment-related mortality.
The current analysis is limited in that we could not as-
sign the Pesaro risk score for most patients with thal-
assemia. It is possible that the 7 patients with
thalassemia major who engrafted and died of a treat-
ment-related complication were ‘‘high risk.’’ However,
the most common cause of treatment failure, although
not necessarily of mortality, was graft failure, which
cannot be predicted with the Pesaro risk score. There-
fore, the lack of assignment of this risk score does not
underscore the validity of our observation for patients
with thalassemia after CBT.
The observed high rate of graft failure after unre-
lated CB transplantation is related to the number of
nucleated cells infused. As observed for other nonma-
lignant diseases, the cell dose of the UCB unit
was a major factor associated with engraftment
and DFS as well as HLA [30,31]. In the current
analysis, engraftment and DFS were higher after
transplantation of UCB units containing .5  107
nucleated cells/kg at the time of infusion, similar to
that observed in patients with Fanconi anemia [32].
We know that in the setting ofHLAmatched sibling
and unrelated adult donor BM transplants, increasing
pretransplant immune suppression to a myeloablative
conditioning regimen is associatedwith a lower graft fail-
ure rate of 5% [4,33]. For UCB, only 1 group has
reported 80% DFS at 2 years specifically in recipients
of busulfan, cyclophosphamide, and ATG limited to
patients with thalassemia [15]. Although most patients
in the current analysis received a myeloablative trans-
plant conditioning regimen with ATG or alemtuzumab,
DFSwas not as good as previously reported by Jaing and
colleagues [15]. However, the heterogeneity of trans-
plant conditioning regimens in the current analysis pre-
cludes definitive recommendations other than increasing
pretransplant immune suppression to facilitate engraft-
ment. New conditioning regimens more likely to effect
sustained engraftment are needed for this patient popu-
lation.
Indeed, graft failure after umbilical CBT is multi-
factorial including known factors such as disease,
HLA-disparity, cell dose, conditioning regimen, aswell as several unknown and unmeasured factors that
may include matching at HLA-C locus and presence
of HLA antibodies [34]. Recently, the Japanese group
[35] reported on the impact of anti-HLA antibodies
on the engraftment rate. In this series among 386
UCBT, 89 tested positive for anti-HLA antibodies,
and 20 cases had specificity against the cord blood
HLA. Patients with antibodies against the cord blood
graft had significant higher graft failure rate. We do
not have donor-recipient samples, which prevent us
from examining for the impact of HLA antibodies on
graft failure in our population. Additionally, all patients
in the current analysis were transfused prior to trans-
plantation, and we cannot exclude the possibility of al-
loimmunization and its effect on engraftment. Taken
together, the transplantation strategies using unrelated
CB as the stem cell source is suboptimal for patients
with hemoglobinopathy. Graft failure remains a major
limitation to success, and the continuing use of CB for
this disease must be discouraged outside of well-
designed novel clinical trials. One potential strategy
may be the use of 2 CB units in order to achieve the de-
sired cell dose as has been done in patients with malig-
nancy [36]. However, early reports suggest that the
double CB transplant approach may be associated
with a higher rate of aGVHD, which may add to the
burden of morbidity and mortality for such a patient
population [37]. Indeed, no data have yet been reported
on double CB transplant for hemoglobinopathies.
An alternative is HSC transplantation [11]. Results
are encouraging, and a larger series is needed to con-
firm the observed success after this strategy. Other
strategies such as preimplantation genetics and embryo
selection [38] or gene therapy to correct the beta-
globin synthesis [39] for those with access to this
technology are currently under investigation and may
optimize outcomes.ACKNOWLEDGMENTS
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